Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.40 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.40 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.39 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 4/20 | 0.37 |
| ▸ | POLB | P06746 | 2/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1106734 | 0.99 | ALDH1A1 (0.41) | ALDH1A1L3MBTL1KMT2ASLC6A2SLC6A3 | |
| SCHEMBL5902320 | 0.93 | ALDH1A1 (0.47) | ALDH1A1L3MBTL1KMT2ASLC6A2SLC6A3 | |
| SCHEMBL5903202 | 0.92 | ALDH1A1 (0.46) | ALDH1A1L3MBTL1KMT2ADDB1CRBN | |
| SCHEMBL10091475 | 0.89 | ALDH1A1 (0.41) | ALDH1A1L3MBTL1KMT2ASLC6A2SLC6A3 | |
| SCHEMBL1146214 | 0.88 | ALDH1A1 (0.40) | ALDH1A1L3MBTL1KMT2ASLC6A2SLC6A3 | |
| SCHEMBL12138665 | 0.87 | ALDH1A1 (0.45) | ALDH1A1L3MBTL1KMT2ADDB1CRBN | |
| SCHEMBL12138689 | 0.86 | ALDH1A1 (0.44) | ALDH1A1L3MBTL1KMT2ADDB1CRBN | |
| SCHEMBL18633534 | 0.84 | ALDH1A1 (0.41) | ALDH1A1L3MBTL1KMT2ADDB1CRBN | |
| SCHEMBL14106381 | 0.82 | ALDH1A1 (0.40) | ALDH1A1L3MBTL1KMT2ADDB1CRBN | |
| SCHEMBL1106784 | 0.80 | LMNA (0.33) | ALDH1A1L3MBTL1KMT2ALMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170073286-A1 | CYCLOALKYL-HYDROXYL COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES | ESPERION THERAPEUTICS, INC. | 2017-03-16 | — | — | US | disclosed |
| US-9006290-B2 | Cycloalkyl-hydroxyl compounds and compositions for cholesterol management and related uses | ESPERION THERAPEUTICS, INC. (US) | 2015-04-14 | — | — | US | disclosed |
| US-20140235723-A1 | CYCLOALKYL-HYDROXYL COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES | ESPERION THERAPEUTICS, INC. (US) | 2014-08-21 | — | — | US | disclosed |
| US-8623915-B2 | Cycloalkyl-hydroxyl compounds and compositions for cholesterol management and related uses | ESPERION THERAPEUTICS, INC. (US) | 2014-01-07 | — | — | US | disclosed |
| US-20130040916-A1 | CYCLOALKYL-HYDROXYL COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES | ESPERION THERAPEUTICS, INC. (US) | 2013-02-14 | — | — | US | disclosed |
| US-8309604-B2 | Cycloalkyl-hydroxyl compounds and compositions for cholesterol management and related uses | ESPERION THERAPEUTICS, INC. (US) | 2012-11-13 | — | — | US | disclosed |
| US-20120172337-A1 | CYCLOALKYL-HYDROXYL COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES | ESPERION THERAPEUTICS, INC. (US) | 2012-07-05 | — | — | US | disclosed |
| US-8153690-B2 | Cycloalkyl-hydroxyl compounds and compositions for cholesterol management | ESPERION THERAPEUTICS, INC. (US) | 2012-04-10 | — | — | US | disclosed |
| US-20120035141-A1 | CYCLOALKYL-HYDROXYL COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT | ESPERION THERAPEUTICS, INC. (US) | 2012-02-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120035141-A1 | CYCLOALKYL-HYDROXYL COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT | PNLIP, NR1H3, NR1H2 | ALDH1A1 1851/4885L3MBTL1 3579/4885KMT2A 4662/4885 |
| US-20120172337-A1 | CYCLOALKYL-HYDROXYL COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES | PNLIP, NR1H3, NR1H2 | ALDH1A1 2139/4885L3MBTL1 3518/4885KMT2A 4652/4885 |
| US-20140235723-A1 | CYCLOALKYL-HYDROXYL COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES | PNLIP, NR1H3, NR1H2 | ALDH1A1 2139/4885L3MBTL1 3518/4885KMT2A 4652/4885 |
| US-20130040916-A1 | CYCLOALKYL-HYDROXYL COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES | PNLIP, NR1H3, NR1H2 | ALDH1A1 2139/4885L3MBTL1 3518/4885KMT2A 4652/4885 |
| US-20170073286-A1 | CYCLOALKYL-HYDROXYL COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES | PNLIP, NR1H3, NR1H2 | ALDH1A1 2139/4885L3MBTL1 3518/4885KMT2A 4652/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.